Association between adiponectin and heart failure risk in the physicians' health study

Obesity

Volumn 21, Issue 4, 2013, Pages 831-834

  Djoussé, Luc ^a,b   Wilk, Jemma B ^a   Hanson, Naomi Q ^c   Glynn, Robert J ^a   Tsai, Michael Y ^c   Gaziano, J Michael ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC)   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN;

ADULT; AGE; AGED; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; EXERCISE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PHYSICIAN; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; QUESTIONNAIRE; RACE; RISK ASSESSMENT; SMOKING; UNITED STATES;

EID: 85027921200     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1002/oby.20260     Document Type: Article

References (36)

1. Rosamond W, Flegal K, Furie K, et al,. Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008; 117: e25-146.
2. Jessup M, Brozena S,. Heart failure. N Engl J Med 2003; 348: 2007-2018.
3. Senni M, Tribouilloy CM, Rodeheffer RJ, et al,. Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation 1998; 98: 2282-2289.
4. Gheorghiade M, Bonow RO,. Chronic heart failure in the United States: a manifestation of coronary artery disease. Circulation 1998; 97: 282-289.
5. Gottdiener JS, Arnold AM, Aurigemma GP, et al,. Predictors of congestive heart failure in the elderly: the Cardiovascular Health Study. J Am Coll Cardiol 2000; 35: 1628-1637.
6. Hunt SA, Baker DW, Chin MH, et al,. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2001; 38: 2101-2113.
7. Kenchaiah S, Evans JC, Levy D, et al,. Obesity and the risk of heart failure. N Engl J Med 2002; 347: 305-313.
8. Kenchaiah S, Sesso HD, Gaziano JM,. Body mass index and vigorous physical activity and the risk of heart failure among men. Circulation 2009; 119: 44-52.
9. Biggs ML, Mukamal KJ, Luchsinger JA, et al,. Association between adiposity in midlife and older age and risk of diabetes in older adults. JAMA 2010; 303: 2504-2512.
10. Laughlin GA, Barrett-Connor E, May S, Langenberg C,. Association of adiponectin with coronary heart disease and mortality: the Rancho Bernardo study. Am J Epidemiol 2007; 165: 164-174.
11. Schulze MB, Shai I, Rimm EB, et al,. Adiponectin and future coronary heart disease events among men with type 2 diabetes. Diabetes 2005; 54: 534-539.
12. Rothenbacher D, Brenner H, März W, Koenig W,. Adiponectin, risk of coronary heart disease and correlations with cardiovascular risk markers. Eur Heart J 2005; 26: 1640-1646.
13. von Eynatten M, Hamann A, Twardella D, et al,. Relationship of adiponectin with markers of systemic inflammation, atherogenic dyslipidemia, and heart failure in patients with coronary heart disease. Clin Chem 2006; 52: 853-859.
14. Wannamethee SG, Tchernova J, Whincup P, et al,. Associations of adiponectin with metabolic and vascular risk parameters in the British Regional Heart Study reveal stronger links to insulin resistance-related than to coronory heart disease risk-related parameters. Int J Obes (Lond) 2007; 31: 1089-1098.
15. Snehalatha C, Mukesh B, Simon M, et al,. Plasma adiponectin is an independent predictor of type 2 diabetes in Asian indians. Diabetes Care 2003; 26: 3226-3229.
16. Choi KM, Lee J, Lee KW, et al,. Serum adiponectin concentrations predict the developments of type 2 diabetes and the metabolic syndrome in elderly Koreans. Clin Endocrinol (Oxf) 2004; 61: 75-80.
17. Yamamoto Y, Hirose H, Saito I, Nishikai K, Saruta T,. Adiponectin, an adipocyte-derived protein, predicts future insulin resistance: two-year follow-up study in Japanese population. J Clin Endocrinol Metab 2004; 89: 87-90.
18. Shibata R, Izumiya Y, Sato K, et al,. Adiponectin protects against the development of systolic dysfunction following myocardial infarction. J Mol Cell Cardiol 2007; 42: 1065-1074.
19. Shibata R, Ouchi N, Ito M, et al,. Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat Med 2004; 10: 1384-1389.
20. Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N Engl J Med 1989; 321: 129-135.
21. Ho KK, Anderson KM, Kannel WB, Grossman W, Levy D,. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 1993; 88: 107-115.
22. Djoussé L, Gaziano JM,. Alcohol consumption and risk of heart failure in the Physicians' Health Study I. Circulation 2007; 115: 34-39.
23. Djoussé L, Driver JA, Gaziano JM,. Relation between modifiable lifestyle factors and lifetime risk of heart failure. JAMA 2009; 302: 394-400.
24. Pischon T, Girman CJ, Hotamisligil GS, et al,. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004; 291: 1730-1737.
25. Tsutamoto T, Tanaka T, Sakai H, et al,. Total and high molecular weight adiponectin, haemodynamics, and mortality in patients with chronic heart failure. Eur Heart J 2007; 28: 1723-1730.
26. George J, Patal S, Wexler D, et al,. Circulating adiponectin concentrations in patients with congestive heart failure. Heart 2006; 92: 1420-1424.
27. Ingelsson E, Risérus U, Berne C, et al,. Adiponectin and risk of congestive heart failure. JAMA 2006; 295: 1772-1774.
28. Frankel DS, Vasan RS, D'Agostino RB Sr, et al,. Resistin, adiponectin, and risk of heart failure the Framingham offspring study. J Am Coll Cardiol 2009; 53: 754-762.
29. Okamoto H,. Can adiponectin be a novel metabolic biomarker for heart failure ? Circ J 2009; 73: 1012-1013.
30. Sam F, Duhaney TA, Sato K, et al,. Adiponectin deficiency, diastolic dysfunction, and diastolic heart failure. Endocrinology 2010; 151: 322-331.
31. Weyer C, Funahashi T, Tanaka S, et al,. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86: 1930-1935.
32. Daimon M, Oizumi T, Saitoh T, et al,. Decreased serum levels of adiponectin are a risk factor for the progression to type 2 diabetes in the Japanese Population: the Funagata study. Diabetes Care 2003; 26: 2015-2020.
33. Chow WS, Cheung BM, Tso AW, et al,. Hypoadiponectinemia as a predictor for the development of hypertension: a 5-year prospective study. Hypertension 2007; 49: 1455-1461.
34. Iwashima Y, Katsuya T, Ishikawa K, et al,. Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension 2004; 43: 1318-1323.
35. Kizer JR, Arnold AM, Jenny NS, et al,. Longitudinal changes in adiponectin and inflammatory markers and relation to survival in the oldest old: the Cardiovascular Health Study All Stars study. J Gerontol A Biol Sci Med Sci 2011; 66: 1100-1107.
36. Kizer JR, Arnold AM, Benkeser D, et al,. Total and high-molecular-weight adiponectin and risk of incident diabetes in older people. Diabetes Care 2012; 35: 415-423.